No clinical trials have yet reported the efficacy of tazemetostat in patients with melanoma, but preclinical studies have suggested EZH2-targeted therapies may interfere with melanoma progression and metastasis and could be a target for combinations with either ICI or BRAF-targeted therapy26. This evidence concerns the gene BRAF and melanoma.